{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:45:58Z","timestamp":1782708358063,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare and aggressive lymphoma for which no standard frontline treatment has been established. Presentation in the nasal cavity is particularly uncommon. We report the case of a 39-year-old man who presented with progressive left-sided nasal obstruction, epistaxis, and bilateral cervical lymphadenopathy. Imaging revealed a left sinonasal\/nasopharyngeal mass, bilateral cervical lymphadenopathy, diffuse skeletal hypermetabolism, markedly elevated lactate dehydrogenase, and focal bone marrow involvement. Histopathologic examination showed a plasmablastic neoplasm with strong granular cytoplasmic ALK expression. The tumor cells were positive for CD138, MUM1, EMA, and kappa light chain, but negative for CD20, CD19, CD79a, CD3, CD30, CD56, and EBER. Fluorescence\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridization confirmed ALK rearrangement, and RNA sequencing together with RT-PCR identified a CLTC::ALK fusion (CLTC exon 31::ALK exon 20). The patient was diagnosed with Ann Arbor stage IVB ALK+ LBCL. Disease progression after initial CVAD chemotherapy and persistent disease after CVAD-E prompted the addition of alectinib from cycle 3, with complete metabolic response on PET-CT after cycle 4. Consolidation with Hyper-CVAD plus concurrent alectinib was followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplant alectinib maintenance. The patient remains in complete remission 10 months after diagnosis. This case illustrates the diagnostic value of integrated morphologic and molecular assessment in CD20-negative plasmablastic lymphoid neoplasms and suggests that incorporating ALK inhibition into multimodal therapy may be a reasonable strategy for selected patients with ALK+ LBCL.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1876454","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:39Z","timestamp":1782707139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ALK-positive large B-cell lymphoma presenting in the nasal cavity with CLTC::ALK fusion: a case report of alectinib-integrated therapy followed by autologous hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiong","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v89.5.1483.1483_1483_1490","article-title":"A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100441","article-title":"Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissues: B-cell neoplasms","volume":"37","author":"Medeiros","year":"2024","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/PAS.0000000000000753","article-title":"ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature","volume":"41","author":"Pan","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.05.014","article-title":"ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases","volume":"56","author":"Wang","year":"2024","journal-title":"Pathol (Phila)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0786","article-title":"ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases","volume":"102","author":"Gascoyne","year":"2003","journal-title":"Blood"},{"key":"B7","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literature","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70058","article-title":"Multi-institutional study of ALK-positive large B-cell lymphoma: outcomes in the era of ALK inhibitors and biologically informed therapies","volume":"100","author":"Atallah-Yunes","year":"2025","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015443","article-title":"Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007537","article-title":"Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma kinase-positive large B-cell lymphoma","volume":"7","author":"Takiar","year":"2023","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm1249","article-title":"Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target","volume":"11","author":"Chiarle","year":"2005","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1480880","article-title":"Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06000-7","article-title":"Alectinib maintenance therapy following cord blood transplantation for relapsed pediatric anaplastic large cell lymphoma with central nervous system involvement","volume":"103","author":"Tamefusa","year":"2024","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jaad.2021.07.050","article-title":"Risk of lymphohematologic Malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis","volume":"86","author":"Bellinato","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:40Z","timestamp":1782707140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1876454"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876454","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1876454"}}